Prolotherapy in Knee Osteoarthritis

Comparison of the Effectiveness of Intra-articular Prolotherapy versus Peri-articular Prolotherapy on Pain Reduction and Function Improvement in Patients with Knee Osteoarthritis with Effusion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180623040209N1

Enrollment

Registered

2018-08-04

Start date

2018-08-06

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis. Bilateral primary osteoarthritis of knee

Interventions

Intervention 1: In the first group patients lies on bed, patient’s knee with placing a pillow under it flexes to 30 degrees then practitioner prepare the knee and injects 8 ml of 10% hyper tonic dextr

Eligibility

Sex/Gender

All

Age

38 Years to 70 Years

Inclusion criteria

Inclusion criteria: Negative Ballottement Test Negative Fluid Wave Test Age from 38 to 70 years in both sexes Suffering from Knee Osteoarthritis with effusion based on clinical criteria of American College of Rheumatology Suffering from grades 2 and 3 of Knee Osteoarthritis based on Kellgern and Lawrence Grading Scale Complain of knee pain at least for three months before study Knee crepitation at least for three months before study Knee joint stiffness at least for three months before study

Exclusion criteria

Exclusion criteria: Foot deformity Sever Genu Valgum Any infection affecting the knee skin Any intra or peri articular injection for the last three months before the study History of knee joints rheumatic or inflammatory disease History of total knee arthtoplasty Uncontrolled diabetes with HbA1c more than 7.5% BMI more than 42 History of knee trauma or fracture for the last three months before the study History of acute lumbosacral radiculopathy or peripheral neuropathy History of cancer Bleeding disorders Pregnancy Severe Genu Varum

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Before first injections, 4 and 8 weeks after first injection. Method of measurement: Visual Analog Scale (VAS).;Function. Timepoint: Before first injections, 4 and 8 weeks after first injection. Method of measurement: The WOMAC questionnaire consists of 24 items divided into 3 sub scales: Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing. Stiffness (2 items): after first waking and later in the day. Physical Function (17 items): stair use, rising from sitting, standing, bending, walking, getting in/out of a car, shopping, putting on/taking off socks, rising from bed, lying in bed, getting in/out of bath, sitting, getting on/off toilet, heavy household duties, light household duties.	—

Measure

Time frame

Pain. Timepoint: Before first injections, 4 and 8 weeks after first injection. Method of measurement: Visual Analog Scale (VAS).;Function. Timepoint: Before first injections, 4 and 8 weeks after first injection. Method of measurement: The WOMAC questionnaire consists of 24 items divided into 3 sub scales: Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing. Stiffness (2 items): after first waking and later in the day. Physical Function (17 items): stair use, rising from sitting, standing, bending, walking, getting in/out of a car, shopping, putting on/taking off socks, rising from bed, lying in bed, getting in/out of bath, sitting, getting on/off toilet, heavy household duties, light household duties.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPooria Amin Safaei

Shiraz University of Medical Sciences

aminsafaei@sums.ac.ir+98 71 3230 5645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026